Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker‐Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers Initiative
Annals of Neurology · 2026-10 · 100 (S38)
DOI: 10.1002/ana.78246 ↗Kurz gefasst
Editorial in der Zeitschrift Annals of Neurology, online erschienen am 14.05.2026. Verfasst von Ethan G Brown und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
To better understand the earliest stages of alpha‐synucleinopathy, the Parkinson's Progression Markers Initiative (PPMI) has enrolled participants prior to the diagnosis of Parkinson's disease (PD) or dementia with Lewy Bodies (DLB). In this review, we describe lessons learned from prior enrollment and current strategies for PPMI eligibility. Severe hyposmia remains the strongest clinical predictor of aggregated synuclein as measured by a positive cerebrospinal fluid alpha‐synuclein seed amplification assay (CSF aSyn SAA). CSF aSyn SAA is positive before dopamine transporter binding decreases, as measured by dopamine imaging. PPMI's adaptive eligibility criteria have enabled efficient identification of people in the early stage of neuronal synuclein disease defined by biomarkers alone and can inform future therapeutic studies. ANN NEUROL 2026;100:S26–S35
Autor:innen und Institutionen
- Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA.
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA.
- Department of Psychiatry, Rutgers University, Robert Wood Johnson Medical School, Piscataway, NJ.
- Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL.
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN.
- Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
ORCID-Profile: Ethan G Brown, Tanya Simuni, Christine Klein, Ronald B Postuma
Zitieren
APA
Brown, E. G., Chahine, L. M., Dobkin, R. D., Simuni, T., Foroud, T., Heathers, L. E. A., Tropea, T. F., Stanley, C. E., McMahon, B. A., Brüggemann, N., Klein, C., Postuma, R. B., Johnson, N. S., Gochanour, C., Caspell-Garcia, C., Kurth, R., Brumm, M. C., Coffey, C. S., Marek, K., …, & Parkinson's Progression Markers Initiative (2026). Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker‐Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers Initiative. Annals of Neurology, 100(S38). https://doi.org/10.1002/ana.78246
Vancouver
Brown EG, Chahine LM, Dobkin RD, Simuni T, Foroud T, Heathers LEA, et al. Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker‐Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers Initiative. Annals of Neurology. 2026;100(S38). doi:10.1002/ana.78246
BibTeX
@article{Brown2026,
author = {Brown, Ethan G and Chahine, Lana M and Dobkin, Roseanne D and Simuni, Tanya and Foroud, Tatiana and Heathers, Laura E A and Tropea, Thomas F and Stanley, Craig E and McMahon, Bridget A and Brüggemann, Norbert and Klein, Christine and Postuma, Ronald B and Johnson, Noah S and Gochanour, Caroline and Caspell-Garcia, Chelsea and Kurth, Ryan and Brumm, Michael C and Coffey, Christopher S and Marek, Kenneth and Tanner, Caroline M and Parkinson's Progression Markers Initiative, Parkinson's Progression Markers Initiative},
title = {Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker‐Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers Initiative},
journal = {Annals of Neurology},
year = {2026},
volume = {100},
number = {S38},
doi = {10.1002/ana.78246}
}
EUVIMED